Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
JERSEY CITY, N.J., April 06, 2016 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 15th Annual Needham Healthcare Conference at The Westin Grand Central Hotel in New York City on Wednesday, April 13, 2016 at 12:10 p.m. ET.
A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781.235.3060 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
